Alpha Cognition Inc. Common Stock (ACOG) ist ein börsennotiertes Unternehmen im Finanzdienstleistungen Sektor, tätig in der Financial - Conglomerates Branche. Der Hauptsitz des Unternehmens ist in Vancouver, BC, Canada. Der aktuelle CEO ist Michael E. McFadden.
ACOG hat IPO-Datum 2024-11-12, 5 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $102.82M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
